• Mashup Score: 0

    Coronavirus disease 2019 (COVID-19) is a highly contagious viral disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has various effects on asthma, allergic rhinitis, atopic dermatitis, and urticaria and may change the course of the disease depending on the severity of the infection and control status of the disease. Conversely, these diseases may also impact the course of COVID-19. Patients with chronic urticaria and atopic dermatitis may have COVID-19–induced disease exacerbations and biological treatments reduce the risk of exacerbations.

    Tweet Tweets with this article
    • In Press! #COVID19 and Its #Impact on Common #Diseases in the #Allergy #Clinics #JACIIPCOVID https://t.co/eE5siib12c

  • Mashup Score: 0

    Cockroach, dust mite, cat, dog, mouse, and molds are major indoor allergens that have been associated with the development of allergic diseases and disease morbidity in allergen-sensitized individuals. Physical characteristics, such as allergen particle size, hydrophobicity, and charge, can determine an allergen’s propensity to become airborne, location of respiratory tract penetration, and ability to elicit IgE responses in genetically predisposed individuals. Standardization and recent advancements in indoor allergen assessment serve to identify sources and distribution of allergens in a patient’s home and public environment, inform public policy, and monitor the efficacy of allergen avoidance and therapeutics.

    Tweet Tweets with this article
    • In Current Issue! #Indoor #Environmental #Exposures and Their #Relationship to #Allergic #Diseases https://t.co/AlzANNK5pS https://t.co/cj3oA0mF2a

  • Mashup Score: 1

    July 14, 2023 — Eli Lilly and Company and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases.  Versanis’ lead asset is bimagrumab, a monoclonal antibody that binds activin type II A and B receptors to block activin and…

    Tweet Tweets with this article
    • @DAICeditor @EliLillyandCo @VersanisBio1 A definitive agreement was reached for Lilly to acquire Versanis, a private clinical-stage #biopharmaceutical company focused on the #development of new #medicines for the treatment of #cardiometabolic #diseases: https://t.co/GFLoVTAG3B

  • Mashup Score: 1

    Hospitals in England experience extremely high levels of bed occupancy in the winter. In these circumstances, vaccine-preventable hospitalisations due to seasonal respiratory infections have a high cost because of the missed opportunity to treat other patients on the waiting list. This paper estimates the number of hospitalisations that current vaccines against influenza, pneumococcal disease…

    Tweet Tweets with this article
    • #Vaccine -Preventable #Hospitalisations from #Seasonal #Respiratory #Diseases: What Is Their True Value? https://t.co/MJ3kEmUYly https://t.co/WNdVPpappJ

  • Mashup Score: 0

    May 15, 2023 — Cardio Diagnostics Holdings, Inc, a precision cardiovascular medicine company, today announced the availability of its CardioInnovate360 research-use-only (RUO) solution for biopharmaceutical companies that have and/or are developing therapeutics for cardiovascular disease (CVD) conditions or associated co-morbidities. According to Precedence Research, the global cardiovascular…

    Tweet Tweets with this article
    • @DAICeditor @CardioDiag This #research-use-only offering supports the discovery, development, and validation of novel #biopharmaceuticals for the assessment and management of #cardiovascular #diseases. https://t.co/3SBvI9F7dW